Lv617
2890 积分 2024-03-06 加入
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review
2天前
已完结
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
3天前
已完结
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial
3天前
已完结
Commentary on Endotypes in Chronic Spontaneous Urticaria: Where we go wrong
5天前
已完结
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
6天前
已完结
Axial Spondyloarthritis
9天前
已完结
Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions
16天前
已完结
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
19天前
已完结
Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives
21天前
已完结
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
22天前
已完结
皖公网安备34019202002308
